The Synucleinopathies: Twenty Years On

2017/03/06 by Michel Goedert, Ross Jakes, Maria Grazia Spillantini · 2 citations
Medicine · Neuroscience · Psychology · #Parkinson's Disease Mechanisms and Treatments #Neurological disorders and treatments #Genetic Neurodegenerative Diseases #Synucleinopathies #Parkinson's disease #Neuroscience #Medicine #Alpha-synuclein #Psychology #Disease #Internal medicine

paper · pdf · doi:10.3233/jpd-179005

openalex publication_date 2017/03/06 · openalex created_date 2022/02/08 · openalex updated_date 2026/07/22

Abstract

In 2017, it is two hundred years since James Parkinson provided the first complete clinical description of the disease named after him, fifty years since the introduction of high-dose D,L-DOPA treatment and twenty years since α-synuclein aggregation came to the fore. In 1998, multiple system atrophy joined Parkinson's disease and dementia with Lewy bodies as the third major synucleinopathy. Here we review our work, which led to the identification of α-synuclein in Lewy bodies, Lewy neurites and Papp-Lantos bodies, as well as what has happened since. Some of the experiments described were carried out in collaboration with ML Schmidt, JQ Trojanowski and VMY Lee.

Citations

• α-Synuclein in Lewy bodies
• MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy
• A Drosophila model of Parkinson's disease
• PHASE AND ELECTRON MICROSCOPIC OBSERVATIONS OF LEWY BODIES AND MELANIN GRANULES IN THE SUBSTANTIA NIGRA AND LOCUS CAERULEUS IN PARKINSONʼS DISEASE
• Staging of brain pathology related to sporadic Parkinson’s disease
• MDS clinical diagnostic criteria for Parkinson's disease
• α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy?
• Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes
• Neuropathological basis of nonmotor manifestations of Parkinson's disease
• Aromatic Amino Acids and Modification of Parkinsonism
• Modification of Parkinsonism — Chronic Treatment with L-Dopa

Cited by

• Diffuse Lewy body disease
• Dementia with Lewy bodies [wikipedia]